NOVOMEDLINK™

This page contains information about Novo Nordisk products.

Proven dosing accuracy with Levemir® FlexPen®1

Easy and convenient insulin delivery

*Needles are sold separately and may require a prescription in some states.

Injection force

Levemir® FlexPen® versus Lantus® SoloSTAR®

Injection force of Levemir® FlexPen® and Lantus® SoloSTAR® were tested. Injection force was measured in 24 unused devices of next generation FlexPen® fitted with NovoFine® 32G Tip needles, SoloSTAR® fitted with NovoFine® 32G Tip needles, and SoloSTAR® fitted with BD Micro-Fine 31G needles. Each pen was tested delivering a dose of 60 units at constant injection speeds of 4, 6, and 8 mm/sec.2

Adapted from Rissler et al, 2008.2

FlexPen® offers many additional benefits

  • The #1 selling prefilled insulin pen in the world3
  • Available for the same copay as vial/syringe on most managed care plans4†
  • Proven accuracy1
  • Requires low injection force, making it easy to press
  • Easy to learn, easy to use, and easy to teach
  • Color branding on pens and packaging for easy insulin identification
  • Recommended for use with NovoFine® needles
    • NovoFine® 32G Tip with SuperFlow Technology™ designed to enhance flow rate and reduce dosing force when making the injection
    • 90% of patients surveyed found NovoFine® 30G needles practically pain-free5

Learn more about the dosing and delivery of Levemir®

Formulary lookup

†Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative costs. Formulary status is subject to change.

References:

  1. Pfützner A, Reimer T, Hohberg C, Frøkjær LPF, Jørgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curr Med Res Opin. 2008;24(9):2545-2549.
  2. Rissler J, Jørgensen C, Rye Hansen M, Hansen N-A. Evaluation of the injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother. 2008;9(13):2217-2222.
  3. IMS Health Inc. IMS MIDAS (12 months ending September 2009).
  4. Data on file, Novo Nordisk, Inc., Princeton, NJ.
  5. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20(3):486-496.

  1. Levemir® (insulin detemir [rDNA origin] injection) Indications and Usage

    Levemir® is indicated for once- or twice-daily subcutaneous administration for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

    Levemir® Important Safety Information

    Levemir® is contraindicated in patients hypersensitive to insulin detemir or one of its excipients.

    Levemir® should not be diluted or mixed with any other insulin preparations.

    Hypoglycemia is the most common adverse effect of all insulin therapies, including Levemir®. As with other insulins, the timing of hypoglycemic events may differ among various insulin preparations. Glucose monitoring is recommended for all patients with diabetes. Levemir® is not to be used in insulin infusion pumps. Any change of insulin dose should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may require adjustment.

    Needles and Levemir® FlexPen® must not be shared.

    Inadequate dosing or discontinuation of treatment may lead to hyperglycemia and, in patients with type 1 diabetes, diabetic ketoacidosis. Insulin may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy. Dose and timing of administration may need to be adjusted to reduce the risk of hypoglycemia in patients being switched to Levemir® from other intermediate or long-acting insulin preparations. The dose of Levemir® may need to be adjusted in patients with renal or hepatic impairment.

    Other adverse events commonly associated with insulin therapy may include injection site reactions (on average, 3% to 4% of patients in clinical trials) such as lipodystrophy, redness, pain, itching, hives, swelling, and inflammation. Less common but more serious are severe cases of generalized allergy, including anaphylactic reaction, which may be life threatening.

    *Whether these observed differences represent true differences in the effects of Levemir®, NPH insulin, and insulin glargine is not known since these trials were not blinded and the protocols (e.g., diet and exercise instructions and monitoring) were not specifically directed at exploring hypotheses related to weight effects of the treatments compared. The clinical significance of the observed differences in weight has not been established.

    Please see Prescribing InformationPrescribing Information.

FlexPen®, Levemir®, and NovoFine® are registered trademarks of Novo Nordisk A/S. NovoMedlink™ and SuperFlow Technology™ are trademarks of Novo Nordisk A/S.

Lantus® and SoloSTAR® are registered trademarks of sanofi-aventis U.S. LLC.
Micro-Fine® is a registered trademark of Becton, Dickinson and Co.